23 >100m 48 >6,800 people with bleeding disorders (PWBD) treated >1,800 people with bleeding disorders (PWBD) on prophylaxis >12,500 acute bleeds treated >687 surgeries supported Advancing access through partnerships During FY2025, CSL continued its existing partnership with the World Federation of Haemophilia (WFH), which began in 2009, as part of CSL’s continued support of the Humanitarian Aid Program. CSL’s contributions to the WFH Humanitarian Aid program make life‑changing improvements to people with no or limited access to care for bleeding disorders. The donation allows people with no or limited access to vital therapies for the bleeding disorder haemophilia A to receive the care they need in 48 developing countries. CSL manufactures this product specifically for donation purposes and it has a shelf life of three years, which allows WFH to widely distribute this life‑saving therapy as needed. CSL’s contribution is especially important in providing and increasing prophylaxis therapy for children and adults. This can help decrease the number of acute bleeding incidents and improve surgery outcomes. CSL’s donation has helped treat over 12,500 acute bleeds, with more than 6,800 people with bleeding disorders (PWBD) treated and over 1,800 PWBD receiving ongoing prophylaxis therapy to prevent bleeds. Supporting 23 developing countries as prioritised by the World Health Organization (WHO) and with the capabilities and resources available to provide continued prophylaxis treatments and major surgeries. Data is based on the calendar year 2024 and reflects CSL’s second full calendar year of the five‑year commitment. Providing access in the event of influenza pandemic As a leader in public health protection, CSL Seqirus has now partnered with over 30 governments around the world. Most recently in April 2025, CSL Seqirus has been contracted by the Health Emergency Preparedness and Response Authority’s (HERA), part of the European Commission, to support the region’s pandemic preparedness plans. Under the terms of the agreement, HERA has reserved 27 million doses of pandemic influenza vaccine from CSL Seqirus’ Liverpool manufacturing site. In the event of an influenza pandemic 17 participating European Union (EU) and European Economic Area (EEA) countries can access these doses. The contract requires CSL to be prepared to rapidly manufacture and deliver these vaccine doses against the influenza strain identified by the WHO when an influenza pandemic is declared. This agreement reinforces CSL’s global leadership and highlights the vital role of reservation mechanisms in proactive pandemic preparedness. The highly pathogenic avian influenza outbreaks continue to remind us of the threat posed by influenza across the globe. Healthier Communities Access and affordability commitments: CSL is committed to advancing equitable access to its medicines and vaccines by designing access and affordability programs to serve vulnerable populations and expand strategic donations. Through extension of CSL’s existing World Federation of Haemophilia (WFH) partnership, by FY2030, CSL aims to donate products that enable 2,100 people with bleeding disorders to access prophylaxis therapy across 25 low- and middle-income countries. New commitment: Further, in support of reaching more communities and patients, through discounted products, CSL announces a new aspirational commitment to treat up to 450,000 people with anaemia in at least three low- and middle-income countries with CSL Vifor’s Ferinject® by FY2030. IUs of coagulation factor donated to WFH Humanitarian Aid program WFH defined developing countries in receipt of CSL’s donated coagulation factors countries with prophylaxis or major surgeries (cumulative) 28 Healthier World During the 2024 calendar year
RkJQdWJsaXNoZXIy MjE2NDg3